AMO unveils new silicone Tecnis IOL

Article

Advanced Medical Optics (AMO) announced the launch of the Tecnis CL intraocular lens (IOL) at the XXIV congress of the ESCRS.

Advanced Medical Optics (AMO) announced the launch of the Tecnis CL intraocular lens (IOL) at the XXIV congress of the ESCRS.

The new lens features blue modified C PMMA haptics for improved visibility and easier implantation, frosted OptiEdge design for reduced edge glare and reduced posterior capsule opacification and highly biocompatible silicone. The Tecnis CL can be implanted using the UNFOLDER Silver Series Implantation Systems and the Silver Advanced Cartridge through a 2.8 mm incision.

The new lens acts as a permanent replacement to the Z9000 and Z9001 Tecnis silicone IOL models.

In August of this year, the US Centers for Medicare and Medicaid Services (CMS) extended New Technology Intraocular Lens (NTIOL) status to the lens. Tecnis and Tecnis CL are the only FDA approved IOLs that are indicated for reducing spherical equivalent, improving visual function and improving night driving performance.

The Tecnis CL is now available in Europe and AMO intends to start shipping the lens to the US, Canada and Asia Pacific within the next month and to Japan by mid-2007.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Related Content
Moorfields, Topcon, IoO announce partnership launch of Cascader

Moorfields, Topcon, IoO announce partnership launch of Cascader

Kassi Filkins
May 7th 2025
Article

Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease.

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
An image of an eye behind glasses. Digital input on the glasses conveys concept of artificial intelligence and computing. Image credit: ©Arsenii – stock.adobe.com

ZEISS debuts Research Data Platform, highlights Boehringer Ingelheim partnership

Martin David Harp
May 2nd 2025
Article

Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025

LuxIA receives CE-MDR certification

LuxIA receives CE-MDR certification

Sydney M Crago
May 1st 2025
Article

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

An image of a map of Europe with lights all over the surface. Concept image for European Medicines Agency, European Commission approval of Thyroid Eye Disease medication. Image credit: ©Pickoloh – stock.adobe.com

EMA CHMP adopts positive opinion for teprotumumab (Tepezza, Amgen) marketing authorisation application

Hattie Hayes
April 30th 2025
Article

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment

UVC light can be used as a noninvasive treatment for microbial keratitis. Image courtesy of Photon Therapeutics. Concept image for cornea treatment with ultraviolet light.

The future of microbial keratitis treatment is bright

Priyanka Mandal, MBChB FRCOphth;Sunil Shah, MBBS, FRCS(Ed), FRCOphth, FBCLA, FWCRS
April 29th 2025
Article

Ultraviolet light’s potential in ocular care extends beyond structural reinforcement to antimicrobial applications, especially for microbial keratitis

© 2025 MJH Life Sciences

All rights reserved.